MENU
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • For Media Inquiries
  • Contact Us
  • 日本語
  • English
Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • For Media Inquiries
  • Contact Us
  • 日本語
  • English
  • About Us
  • Blog
  • Series
  • Category
  • For Media Inquiries
  • Contact Us
  • 日本語
  • English
Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • For Media Inquiries
  • Contact Us
  • 日本語
  • English
  1. Home
  2. Frontiers of Cancer Origin Research

Frontiers of Cancer Origin Research– category –

  • Frontiers of Cancer Origin Research

    The Window Where Cancer Is Born — Progenitor Niche and the Benign-to-Malignant Transition | Frontiers of Cancer Origin Research, Vol. 1

    Reyes et al. Cell May 2026: PDAC's benign-to-malignant transition happens in a rare progenitor-like cell population that assembles a self-reinforcing niche. Tumor-driving and tumor-suppressing programs (p53, CDKN2A, SMAD4) co-activate in these cells. KRAS inhibition or p53 activation collapses the niche and delays malignancy. Vol. 1.
    2026-05-05
1
  • Disclaimer
  • Privacy Policy
  • Sitemap
  • Contact Us
  • 日本語

© Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~.

  • Menu
  • Disclaimer
  • Privacy Policy
  • Sitemap
  • Contact Us
  • 日本語